Gram-positive bacterial infections

Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group

Sarah B. Doernberg, Thomas P. Lodise, Joshua T. Thaden, Jose M. Munita, Sara Cosgrove, Cesar A. Arias, Helen W. Boucher, G. Ralph Corey, Franklin D. Lowy, Barbara Murray, Loren G. Miller, Thomas L. Holland

Research output: Contribution to journalArticle

Abstract

Antimicrobial resistance in gram-positive bacteria remains a challenge in infectious diseases. The mission of the Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG) is to advance knowledge in the prevention, management, and treatment of these challenging infections to improve patient outcomes. Our committee has prioritized projects involving methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) due to the scope of the medical threat posed by these pathogens. Approved ARLG projects involving gram-positive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the impact of vancomycin dosing on patient outcome in MRSA bloodstream infection (BSI); (2) defining, testing, and validating innovative assessments of patient outcomes for clinical trials of MRSA-BSI; (3) testing new strategies for "stepdown" antibiotic therapy for MRSA-BSI; (4) management of staphylococcal BSIs in neonatal intensive care units; and (5) defining the impact of VRE bacteremia and daptomycin susceptibility on patient outcomes. This article outlines accomplishments, priorities, and challenges for research of infections caused by gram-positive organisms.

Original languageEnglish (US)
Pages (from-to)S24-S29
JournalClinical Infectious Diseases
Volume64
DOIs
StatePublished - 2017

Fingerprint

Gram-Positive Bacterial Infections
Methicillin-Resistant Staphylococcus aureus
Infection
Research
Patient Outcome Assessment
Daptomycin
Neonatal Intensive Care Units
Gram-Positive Bacteria
Vancomycin
Bacteremia
Communicable Diseases
Pharmacokinetics
Direction compound
Clinical Trials
Anti-Bacterial Agents
Therapeutics

Keywords

  • Bloodstream infection
  • Clostridium difficile infection
  • Gram-positive bacteria
  • Staphylococcus aureus
  • Vancomycin-resistant enterococci

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Gram-positive bacterial infections : Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. / Doernberg, Sarah B.; Lodise, Thomas P.; Thaden, Joshua T.; Munita, Jose M.; Cosgrove, Sara; Arias, Cesar A.; Boucher, Helen W.; Corey, G. Ralph; Lowy, Franklin D.; Murray, Barbara; Miller, Loren G.; Holland, Thomas L.

In: Clinical Infectious Diseases, Vol. 64, 2017, p. S24-S29.

Research output: Contribution to journalArticle

Doernberg, SB, Lodise, TP, Thaden, JT, Munita, JM, Cosgrove, S, Arias, CA, Boucher, HW, Corey, GR, Lowy, FD, Murray, B, Miller, LG & Holland, TL 2017, 'Gram-positive bacterial infections: Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group', Clinical Infectious Diseases, vol. 64, pp. S24-S29. https://doi.org/10.1093/cid/ciw828
Doernberg, Sarah B. ; Lodise, Thomas P. ; Thaden, Joshua T. ; Munita, Jose M. ; Cosgrove, Sara ; Arias, Cesar A. ; Boucher, Helen W. ; Corey, G. Ralph ; Lowy, Franklin D. ; Murray, Barbara ; Miller, Loren G. ; Holland, Thomas L. / Gram-positive bacterial infections : Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. In: Clinical Infectious Diseases. 2017 ; Vol. 64. pp. S24-S29.
@article{a2f668033b784440aca2ec7da76e426d,
title = "Gram-positive bacterial infections: Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group",
abstract = "Antimicrobial resistance in gram-positive bacteria remains a challenge in infectious diseases. The mission of the Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG) is to advance knowledge in the prevention, management, and treatment of these challenging infections to improve patient outcomes. Our committee has prioritized projects involving methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) due to the scope of the medical threat posed by these pathogens. Approved ARLG projects involving gram-positive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the impact of vancomycin dosing on patient outcome in MRSA bloodstream infection (BSI); (2) defining, testing, and validating innovative assessments of patient outcomes for clinical trials of MRSA-BSI; (3) testing new strategies for {"}stepdown{"} antibiotic therapy for MRSA-BSI; (4) management of staphylococcal BSIs in neonatal intensive care units; and (5) defining the impact of VRE bacteremia and daptomycin susceptibility on patient outcomes. This article outlines accomplishments, priorities, and challenges for research of infections caused by gram-positive organisms.",
keywords = "Bloodstream infection, Clostridium difficile infection, Gram-positive bacteria, Staphylococcus aureus, Vancomycin-resistant enterococci",
author = "Doernberg, {Sarah B.} and Lodise, {Thomas P.} and Thaden, {Joshua T.} and Munita, {Jose M.} and Sara Cosgrove and Arias, {Cesar A.} and Boucher, {Helen W.} and Corey, {G. Ralph} and Lowy, {Franklin D.} and Barbara Murray and Miller, {Loren G.} and Holland, {Thomas L.}",
year = "2017",
doi = "10.1093/cid/ciw828",
language = "English (US)",
volume = "64",
pages = "S24--S29",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Gram-positive bacterial infections

T2 - Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group

AU - Doernberg, Sarah B.

AU - Lodise, Thomas P.

AU - Thaden, Joshua T.

AU - Munita, Jose M.

AU - Cosgrove, Sara

AU - Arias, Cesar A.

AU - Boucher, Helen W.

AU - Corey, G. Ralph

AU - Lowy, Franklin D.

AU - Murray, Barbara

AU - Miller, Loren G.

AU - Holland, Thomas L.

PY - 2017

Y1 - 2017

N2 - Antimicrobial resistance in gram-positive bacteria remains a challenge in infectious diseases. The mission of the Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG) is to advance knowledge in the prevention, management, and treatment of these challenging infections to improve patient outcomes. Our committee has prioritized projects involving methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) due to the scope of the medical threat posed by these pathogens. Approved ARLG projects involving gram-positive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the impact of vancomycin dosing on patient outcome in MRSA bloodstream infection (BSI); (2) defining, testing, and validating innovative assessments of patient outcomes for clinical trials of MRSA-BSI; (3) testing new strategies for "stepdown" antibiotic therapy for MRSA-BSI; (4) management of staphylococcal BSIs in neonatal intensive care units; and (5) defining the impact of VRE bacteremia and daptomycin susceptibility on patient outcomes. This article outlines accomplishments, priorities, and challenges for research of infections caused by gram-positive organisms.

AB - Antimicrobial resistance in gram-positive bacteria remains a challenge in infectious diseases. The mission of the Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG) is to advance knowledge in the prevention, management, and treatment of these challenging infections to improve patient outcomes. Our committee has prioritized projects involving methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) due to the scope of the medical threat posed by these pathogens. Approved ARLG projects involving gram-positive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the impact of vancomycin dosing on patient outcome in MRSA bloodstream infection (BSI); (2) defining, testing, and validating innovative assessments of patient outcomes for clinical trials of MRSA-BSI; (3) testing new strategies for "stepdown" antibiotic therapy for MRSA-BSI; (4) management of staphylococcal BSIs in neonatal intensive care units; and (5) defining the impact of VRE bacteremia and daptomycin susceptibility on patient outcomes. This article outlines accomplishments, priorities, and challenges for research of infections caused by gram-positive organisms.

KW - Bloodstream infection

KW - Clostridium difficile infection

KW - Gram-positive bacteria

KW - Staphylococcus aureus

KW - Vancomycin-resistant enterococci

UR - http://www.scopus.com/inward/record.url?scp=85033445969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033445969&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw828

DO - 10.1093/cid/ciw828

M3 - Article

VL - 64

SP - S24-S29

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -